ArticleJournal of diabetes research2021
Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence.
Article in Journal of diabetes research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Baseline Nonperfusion and Deep Capillary Plexus Ischemia Predict Two-Year Retinal Nonperfusion Progression in Diabetic Retinopathy.Investigative ophthalmology & visual science · 2026Observational
- Predictors of Peripheral Retinal Non-Perfusion in Clinically Significant Diabetic Macular Edema.Journal of clinical medicine · 2024Article
- The Predictors of Early Treatment Effectiveness of Intravitreal Bevacizumab Application in Patients with Diabetic Macular Edema.Diagnostics (Basel, Switzerland) · 2024Article
- Peripheral and central capillary non-perfusion in diabetic retinopathy: An updated overview.Frontiers in medicine · 2023Review
- Subthreshold Micropulse Laser for Diabetic Macular Edema: A Review.Journal of clinical medicine · 2022Review
- Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography.Journal of diabetes research · 2022Article
- Aqueous Level of ANGPTL4 Correlates with the OCTA Metrics of Diabetic Macular Edema in NPDR.Journal of diabetes research · 2022Article
- Ultra-Widefield Fluorescein Angiography Image Brightness Compensation Based on Geometrical Features.Sensors (Basel, Switzerland) · 2021Article
- How to Achieve Near-Normal Visual Acuity with Bevacizumab in Diabetic Macular Edema Patients.Journal of clinical medicine · 2021Article
- Diabetic Macular Edema Treated with 577-nm Subthreshold Micropulse Laser: A Real-Life, Long-Term Study.Journal of personalized medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the relationship between the retinal nonperfusion area (NPA) presence and the effectiveness of bevacizumab treatment (IVB) in patients with diabetic macular edema (DME). It also tested the prognostic usefulness of ultra-wide-field fluorescein angiography (UWFFA) and OptosAdvance software for diabetic retinopathy monitoring. Eighty-nine patients with DME with a macular central subfield thickness (CST) ≥ 250
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.